Previous 10 | Next 10 |
NEW YORK, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today reported financial results and recent corporate highlights for the thi...
NEW YORK, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, announced today that its Phase 1 data on intravenous (IV) tramadol has been p...
NEW YORK, Oct. 18, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced an eAbstract presentation at ANESTHESIOLOGY® 2019, the A...
Fortress Biotech ( FBIO ) has made significant progress since my 11/24/2018 article on the Fortress Biotech Inc. 9.375% Cum Conv Perp Red Pfd Registered Shs Series ( FBIOP ). Although FBIOP remains a speculative issue, it has appreciated in price from $17.58 to $20.00 since my last artic...
Avenue Therapeutics (NASDAQ: ATXI ): Q2 GAAP EPS of -$0.43 misses by $0.09 . More news on: Avenue Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
NEW YORK, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today reported financial results and recent corporate highlights for the seco...
The attack on opioids is intensifying once again, and the circle of companies falling victim is widening. On Aug. 1, Reuters reported that the State of Oklahoma is now making its final efforts to hold Johnson & Johnson (JNJ) responsible. The Trump Administration has decided to restrict a...
NEW YORK, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a specialty pharmaceutical company focused on the development and commercialization of intravenous (IV) tramadol, today announced that Ms. Garrett Ingram has been appointed to its ...
Since providing a detailed overview of Avenue Therapeutics ( ATXI ) in early February, the stock has done virtually nothing. In fact, shares briefly fell below $5 before rebounding strongly after the company’s second Phase 3 results were positive. At roughly $6 per share, the compan...
Avenue Therapeutics, Inc. (ATXI) Investor Update Conference Call June 03, 2019 09:00 AM ET Company Participants Joe Vazzano - CFO Dr. Lucy Lu - President & CEO Dr. Neil Singla - Chief Scientific Officer of Lotus Clinical Research Conference Call Participants Jonathan As...
News, Short Squeeze, Breakout and More Instantly...
Avenue Therapeutics Inc. Company Name:
ATXI Stock Symbol:
NASDAQ Market:
Avenue Therapeutics Inc. Website:
MIAMI, June 20, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced tha...
MIAMI, May 16, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the ...
– Raised a total of $9.4 million in gross proceeds from warrant exercise transactions since January 2024 – MIAMI, May 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutica...